铑(II)可以通过分子内的氮杂C–H插入反应有效地促进芳基氨基甲酸酯底物的活化和环化,从而生成苯并恶唑啉酮。对底物范围的研究表明,该反应在更不稳定的o -C(sp 3)-H键上进行了选择性芳族C(sp 2)-H胺化反应。反向二次KIE的观察结果(P H / P D = 0.42±0.03)表明,芳族亲电取代机理参与了芳基CH酰胺化反应。
N-fluoropyridinium triflate and its derivatives: Useful fluorinating agents
作者:Teruo Umemoto、Kosuke Kawada、Kyoichi Tomita
DOI:10.1016/s0040-4039(00)84980-1
日期:1986.1
N-Fluoropyridinium triflate and its derivatives, stable and nonhygroscopic crystals, were found to be widely applicable reagents for mild and selective fluorination of a variety of organic compounds.
A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.
[EN] PYRROLIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLIDINE
申请人:HOFFMANN LA ROCHE
公开号:WO2011085886A1
公开(公告)日:2011-07-21
The present invention relates to compounds of formula (I) or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
Superparamagnetic Fe<sub>3</sub>
O<sub>4</sub>
Nanoparticles in a Deep Eutectic Solvent: An Efficient and Recyclable Catalytic System for the Synthesis of Primary Carbamates and Monosubstituted Ureas
Superparamagnetic Fe3O4 nanoparticles were used to prepare primary carbamates as well as monosubstituted and N,N‐disubstituted ureas. This efficient phosgene‐free process used urea as an eco‐friendly carbonyl source in the presence of a biocompatible deep eutectic solvent (DES) to provide an inexpensive and attractive route that afforded the products in moderate to excellent yields. (MNP = magnetite nanoparticles
超顺磁性Fe 3 O 4纳米颗粒用于制备氨基甲酸酯以及单取代的和N,N-二取代的脲。这种有效的无光气工艺在生物相容性深共熔溶剂(DES)的存在下将尿素用作环保的羰基来源,从而提供了一种廉价且有吸引力的途径,使产品收率适中至优异。(MNP =磁铁矿纳米颗粒,Ch =胆碱)
Therapeutic Agents 812
申请人:Birch Alan Martin
公开号:US20110065706A1
公开(公告)日:2011-03-17
A compound of formula I
or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as GPR119 modulators, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus, and pharmaceutical compositions containing them.